$689.93
1.65%
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US45168D1046
Symbol
IDXX

IDEXX Laboratories Stock price

$689.93
+53.02 8.32% 1M
+180.51 35.43% 6M
+276.49 66.88% YTD
+266.28 62.85% 1Y
+261.90 61.19% 3Y
+234.56 51.51% 5Y
+622.01 915.80% 10Y
+672.37 3,828.99% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-11.55 1.65%
ISIN
US45168D1046
Symbol
IDXX

New AI Insights on IDEXX Laboratories Insights AI Insights on IDEXX Laboratories

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$55.1b
Enterprise Value
$55.9b
Net debt
$771.7m
Cash
$208.2m
Shares outstanding
80.0m
Valuation (TTM | estimate)
P/E
54.2 | 53.6
P/S
13.2 | 12.8
EV/Sales
13.4 | 12.9
EV/FCF
59.4
P/B
35.3
Financial Health
Equity Ratio
48.4%
Return on Equity
55.7%
ROCE
61.2%
ROIC
35.9%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$4.2b | $4.3b
EBITDA
$1.4b | $1.5b
EBIT
$1.3b | $1.4b
Net Income
$1.0b | $1.0b
Free Cash Flow
$940.2m
Growth (TTM | estimate)
Revenue
8.4% | 10.8%
EBITDA
16.8% | 19.5%
EBIT
17.5% | 19.5%
Net Income
18.6% | 15.9%
Free Cash Flow
18.6%
Margin (TTM | estimate)
Gross
61.7%
EBITDA
34.7% | 35.0%
EBIT
31.3%
Net
24.7% | 23.8%
Free Cash Flow
22.6%
More
EPS
$12.7
FCF per Share
$11.8
Short interest
2.8%
Employees
11k
Rev per Employee
$350.0k
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a IDEXX Laboratories forecast:

15x Buy
68%
7x Hold
32%

Analyst Opinions

22 Analysts have issued a IDEXX Laboratories forecast:

Buy
68%
Hold
32%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,167 4,167
8% 8%
100%
- Direct Costs 1,595 1,595
6% 6%
38%
2,572 2,572
10% 10%
62%
- Selling and Administrative Expenses 1,024 1,024
2% 2%
25%
- Research and Development Expense 242 242
13% 13%
6%
1,446 1,446
17% 17%
35%
- Depreciation and Amortization 140 140
11% 11%
3%
EBIT (Operating Income) EBIT 1,306 1,306
17% 17%
31%
Net Profit 1,027 1,027
19% 19%
25%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Positive
24/7 Wall Street
3 days ago
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR.
Negative
Seeking Alpha
4 days ago
Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT and Communication Services was responsible for about three-quarters of the underperformance in the period. Stock selection in Consumer Discretionary, Financials, and Industrials hampered relative ...
Positive
Investors Business Daily
11 days ago
No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today